Pasithea Therapeutics Corporation (KTTA) Actualités

Form 8-K - Current report

Pasithea Therapeutics Announces Results from 2023 Annual Meeting

SOUTH SAN FRANCISCO, Calif. and MIAMI, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp...

Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models

-- Preclinical data continues to demonstrate PAS-004’s potentially superior properties as compared to FDA...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders

SOUTH SAN FRANCISCO, Calif. and MIAMI, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp...

Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development

-- Company on track to submit PAS-004 IND application in current quarter -- -- Pasithea plans to begin PAS-004...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS

-- Blocking of α5β1 integrin has been shown to improve motor function and increase survival in the SOD1G93A...

Form ARS - Annual Report to Security Holders

Form DEF 14A - Other definitive proxy statements

Form PRE 14A - Other preliminary proxy statements

Form 8-K - Current report

Form SC TO-I/A - Tender offer statement by Issuer: [Amend]

Form 8-K - Current report

Pasithea Therapeutics Corp. Announces Final Results of Tender Offer

PALO ALTO, Calif. and MIAMI, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA...